Literature DB >> 10559099

Persistent preload defect in severe sepsis despite fluid loading: A longitudinal echocardiographic study in patients with septic shock.

F Jardin1, T Fourme, B Page, Y Loubières, A Vieillard-Baron, A Beauchet, J P Bourdarias.   

Abstract

STUDY
OBJECTIVE: To investigate the rate of recovery from septic shock in patients with suspected left ventricular (LV) preload deficiency and LV systolic dysfunction.
DESIGN: A monitoring period was defined by the need for inotropic/vasopressor support, and LV function was assessed daily during this period by bedside two-dimensional echocardiography (2D-ECHO).
SETTING: University hospital ICU. PATIENTS: During a 5-year period, 90 patients with an episode of septic shock (60% with gram-positive bacteria as the causative agent) were consecutively enrolled in the study (mean age, 55 +/- 18 years). Standard volume resuscitation combined with inotropic/vasopressor support was used to maintain systolic arterial pressure > 90 mm Hg. All patients received mechanical ventilation because of associated respiratory failure. The average duration of hemodynamic support was 4.4 +/- 1.6 days. Thirty-four patients were weaned from hemodynamic support during the monitoring period and ultimately recovered (group I). Twenty-eight patients died from refractory circulatory failure during the monitoring period, and 28 died later from ARDS or multiple organ dysfunction syndrome, leading to a 62% overall mortality rate (group II).
METHODS: Daily bedside LV volumes and ejection fraction (LVEF) were recorded using 2D-ECHO. Data obtained at the start (day 1 and day 2) and end of the monitoring period (day n) were compared.
RESULTS: LV end-diastolic volume was within the normal range of our laboratory values in all patients, but was initially smaller in group II than in group I, and remained so despite fluid loading. LVEF was significantly depressed in all patients, resulting in severe reduction in LV stroke volume (LVSV), which was initially more marked in group I. In group I patients, LVEF significantly improved during the monitoring period, resulting in an increase in LVSV.
CONCLUSION: 2D-ECHO changes during hemodynamic support in 90 septic patients confirmed defective LV preload with a propensity to worsen despite fluid loading in nonsurvivors (62% in the present study). Our results are also in agreement with previous studies reporting depressed LV systolic function at the initial phase of septic shock. Since LV dysfunction was more marked in patients who recovered, we suggest that the exact significance of this finding should be reevaluated.

Entities:  

Mesh:

Year:  1999        PMID: 10559099     DOI: 10.1378/chest.116.5.1354

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  68 in total

Review 1.  Fluid responsiveness in mechanically ventilated patients: a review of indices used in intensive care.

Authors:  Karim Bendjelid; Jacques-A Romand
Journal:  Intensive Care Med       Date:  2003-01-21       Impact factor: 17.440

2.  Heart rate as an independent risk factor in patients with multiple organ dysfunction: a prospective, observational study.

Authors:  Robert S Hoke; Ursula Müller-Werdan; Christine Lautenschläger; Karl Werdan; Henning Ebelt
Journal:  Clin Res Cardiol       Date:  2011-11-03       Impact factor: 5.460

3.  Prognosis of left ventricular systolic dysfunction in septic shock patients.

Authors:  M Mukhyaprana Prabhu; Suresh Kumar Yalakala; Ranjan Shetty; Ashok Thakkar; Tulsee Sitapara
Journal:  J Clin Diagn Res       Date:  2015-03-01

Review 4.  Echocardiography in the critically ill: current and potential roles.

Authors:  S Price; E Nicol; D G Gibson; T W Evans
Journal:  Intensive Care Med       Date:  2005-11-16       Impact factor: 17.440

5.  Bedside echocardiographic evaluation of hemodynamics in sepsis: is a qualitative evaluation sufficient?

Authors:  Antoine Vieillard-Baron; Cyril Charron; Karim Chergui; Olivier Peyrouset; François Jardin
Journal:  Intensive Care Med       Date:  2006-07-20       Impact factor: 17.440

6.  Levosimendan in septic shock in patients with biochemical evidence of cardiac dysfunction: a subgroup analysis of the LeoPARDS randomised trial.

Authors:  David B Antcliffe; Shalini Santhakumaran; Robert M L Orme; Josie K Ward; Farah Al-Beidh; Kieran O'Dea; Gavin D Perkins; Mervyn Singer; Daniel F McAuley; Alexina J Mason; Mary Cross; Deborah Ashby; Anthony C Gordon
Journal:  Intensive Care Med       Date:  2019-08-19       Impact factor: 17.440

Review 7.  Clinical significance of echocardiography in patients supported by venous-venous extracorporeal membrane oxygenation.

Authors:  Adriano Peris; Chiara Lazzeri; Giovanni Cianchi; Manuela Bonizzoli; Stefano Batacchi; Pasquale Bernardo; Serafina Valente; Gian Franco Gensini
Journal:  J Artif Organs       Date:  2015-02-24       Impact factor: 1.731

8.  [Levosimendan-no effect on multiorgan failure in septic shock].

Authors:  U Janssens
Journal:  Med Klin Intensivmed Notfmed       Date:  2017-01-20       Impact factor: 0.840

9.  New-Onset Heart Failure and Mortality in Hospital Survivors of Sepsis-Related Left Ventricular Dysfunction.

Authors:  Saraschandra Vallabhajosyula; Jacob C Jentzer; Jeffrey B Geske; Mukesh Kumar; Ankit Sakhuja; Akhil Singhal; Joseph T Poterucha; Kianoush Kashani; Joseph G Murphy; Ognjen Gajic; Rahul Kashyap
Journal:  Shock       Date:  2018-02       Impact factor: 3.454

10.  Cardio-renal syndromes: report from the consensus conference of the acute dialysis quality initiative.

Authors:  Claudio Ronco; Peter McCullough; Stefan D Anker; Inder Anand; Nadia Aspromonte; Sean M Bagshaw; Rinaldo Bellomo; Tomas Berl; Ilona Bobek; Dinna N Cruz; Luciano Daliento; Andrew Davenport; Mikko Haapio; Hans Hillege; Andrew A House; Nevin Katz; Alan Maisel; Sunil Mankad; Pierluigi Zanco; Alexandre Mebazaa; Alberto Palazzuoli; Federico Ronco; Andrew Shaw; Geoff Sheinfeld; Sachin Soni; Giorgio Vescovo; Nereo Zamperetti; Piotr Ponikowski
Journal:  Eur Heart J       Date:  2009-12-25       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.